Akari Therapeutics, Plc (AKTX) News
Follow Akari Therapeutics, Plc (AKTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Akari Therapeutics to showcase novel PH1 ADC payload platform
Akari Therapeutics says it was invited to present its next-generation ADC payload innovation at five U.S. and China conferences in September, with CEO Abizer Gaslightwala delivering keynote and featured talks.
GEOPOLITICS | Sep 08, 2026, 01:17 PM UTC
L
AKTX - Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums - Click
AKTX - Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
EQUITY | Sep 08, 2026, 01:15 PM UTC
L
AKTX - Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
AKTX - Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
EQUITY | Aug 27, 2026, 01:08 PM UTC
L
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
EQUITY | Aug 27, 2026, 01:01 PM UTC
L
AKTX - Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy - Click
AKTX - Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
EQUITY | Aug 18, 2026, 12:53 PM UTC
L
Akari Therapeutics reports Q2 2026 results; AKTX-101 Phase 1 progress
Akari Therapeutics (AKTX) reports its second quarter 2026 financial results and highlights progress of AKTX-101 toward Phase 1 plus a strategic collaboration for its ADC payload platform.
EARNINGS | Aug 13, 2026, 08:15 PM UTC
H
Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Shares of Amazon.com Inc (NASDAQ: AMZN ) rose sharply in pre-market trading after the company posted upbeat financial results for the second quarter. Amazon reported second-quarter revenue of $200.61 billion, beating the
EARNINGS | Jul 31, 2026, 08:50 AM UTC
L
AKTX Akari Therapeutics enters strategic research collaboration with Whitehawk Therapeutics Akari Therapeutics - Co and Whitehawk to conduct
AKTX Akari Therapeutics enters strategic research collaboration with Whitehawk Therapeutics Akari Therapeutics - Co and Whitehawk to conduct preclinical studies of ph1 payload with top1i Adc platform - Collaboration to c
EQUITY | Jul 21, 2026, 11:31 AM UTC
L
moves among today's upgrades NBIS +7.3%, LITE +6.0%, AKTX +5.7%, URBN +3.1%, YETI +2.2%, HOG +1.8%, GPN +1.5%, USB +0.6%, NFLX -1.8% moves a
moves among today's upgrades NBIS +7.3%, LITE +6.0%, AKTX +5.7%, URBN +3.1%, YETI +2.2%, HOG +1.8%, GPN +1.5%, USB +0.6%, NFLX -1.8% moves among today's positive initiations NNBR +8.0%, RNTX +3.2%, SLNH +15.5%, ANTX +9.6
EQUITY | Jul 20, 2026, 01:42 PM UTC
L
AKTX Upgrade from Hold to Buy W/$30.00 PT at Maxim Group
AKTX Upgrade from Hold to Buy W/$30.00 PT at Maxim Group
EQUITY | Jul 20, 2026, 11:49 AM UTC
L
Akari Therapeutics Files Prospectus Related To Resale Of Up To 6M ADSs Representing 480B Ordinary Shares By The Selling Shareholders
SEC Filing
REGULATION | Jul 02, 2026, 09:30 PM UTC
M
12 Health Care Stocks Move
Gainers Universe Pharmaceuticals (NASDAQ: UPC ) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi Therapeutics (NASDAQ: T
EQUITY | Jun 26, 2026, 11:20 PM UTC